These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9853592)

  • 1. Protein-site targeting. Diversification of the drug discovery process.
    Krantz A
    Nat Biotechnol; 1998 Dec; 16(13):1294. PubMed ID: 9853592
    [No Abstract]   [Full Text] [Related]  

  • 2. Drugs targeting protein-protein interactions.
    Chène P
    ChemMedChem; 2006 Apr; 1(4):400-11. PubMed ID: 16892375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Informatics and modeling challenges in fragment-based drug discovery.
    Hubbard RE; Chen I; Davis B
    Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ranking poses in structure-based lead discovery and optimization: current trends in scoring function development.
    Rajamani R; Good AC
    Curr Opin Drug Discov Devel; 2007 May; 10(3):308-15. PubMed ID: 17554857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lead optimization via high-throughput molecular docking.
    Joseph-McCarthy D; Baber JC; Feyfant E; Thompson DC; Humblet C
    Curr Opin Drug Discov Devel; 2007 May; 10(3):264-74. PubMed ID: 17554852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular modeling of hydration in drug design.
    Mancera RL
    Curr Opin Drug Discov Devel; 2007 May; 10(3):275-80. PubMed ID: 17554853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-binding cavities in long-lived biologics: cause for concern but also potential benefit.
    Panayotatos N
    J Clin Pharmacol; 2008 Oct; 48(10):1208-11. PubMed ID: 18812610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the nature of cavities on protein surfaces: application to the identification of drug-binding sites.
    Nayal M; Honig B
    Proteins; 2006 Jun; 63(4):892-906. PubMed ID: 16477622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of drug-protein binding process by employing equilibrium sampling through hollow-fiber supported liquid membrane and Bjerrum and Scatchard plots.
    Barri T; Trtić-Petrović T; Karlsson M; Jönsson JA
    J Pharm Biomed Anal; 2008 Sep; 48(1):49-56. PubMed ID: 18565712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitor focusing: direct selection of drug targets from proteomes using activity-based probes.
    Nomanbhoy TK; Rosenblum J; Aban A; Burbaum JJ
    Assay Drug Dev Technol; 2003 Feb; 1(1 Pt 2):137-46. PubMed ID: 15090140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pocket extraction on proteins via the Voronoi diagram of spheres.
    Kim D; Cho CH; Cho Y; Ryu J; Bhak J; Kim DS
    J Mol Graph Model; 2008 Apr; 26(7):1104-12. PubMed ID: 18023220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physics-based methods for studying protein-ligand interactions.
    Huang N; Jacobson MP
    Curr Opin Drug Discov Devel; 2007 May; 10(3):325-31. PubMed ID: 17554859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Making drugs on proteins: site-directed ligand discovery for fragment-based lead assembly.
    Erlanson DA; Hansen SK
    Curr Opin Chem Biol; 2004 Aug; 8(4):399-406. PubMed ID: 15288250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promiscuity: what protects us, perplexes us.
    Redinbo MR
    Drug Discov Today; 2004 May; 9(10):431-2. PubMed ID: 15109946
    [No Abstract]   [Full Text] [Related]  

  • 15. Chemocavity: specific concavity in protein reserved for the binding of biologically functional small molecules.
    Soga S; Shirai H; Kobori M; Hirayama N
    J Chem Inf Model; 2008 Aug; 48(8):1679-85. PubMed ID: 18642867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular optimization using computational multi-objective methods.
    Nicolaou CA; Brown N; Pattichis CS
    Curr Opin Drug Discov Devel; 2007 May; 10(3):316-24. PubMed ID: 17554858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for dealing with reactive intermediates in drug discovery and development.
    Nassar AE; Lopez-Anaya A
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):126-36. PubMed ID: 14982156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based maximal affinity model predicts small-molecule druggability.
    Cheng AC; Coleman RG; Smyth KT; Cao Q; Soulard P; Caffrey DR; Salzberg AC; Huang ES
    Nat Biotechnol; 2007 Jan; 25(1):71-5. PubMed ID: 17211405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimizing the potential for metabolic activation as an integral part of drug design.
    Evans DC; Baillie TA
    Curr Opin Drug Discov Devel; 2005 Jan; 8(1):44-50. PubMed ID: 15679171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The many roles of computation in drug discovery.
    Jorgensen WL
    Science; 2004 Mar; 303(5665):1813-8. PubMed ID: 15031495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.